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Background/aim: Currently, hepatitis C virus (HCV) infection can be cured by direct-acting antivirals (DAAs). In this study, we aimed
to find the rate of viremia among patients with a positive anti-HCV test and the rate of antiviral treatment given to viremic patients. We
also aimed to reach patients with anti-HCV positivity but not tested for HCV-RNA, and patients, who were diagnosed with HCV-RNA
positivity but received no treatment.
Materials and methods: In this study, individuals tested for anti-HCV in Tokat Gaziosmanpaşa University Research and Application Hospital
in the period between January 2010 and January 2020 were reviewed retrospectively. Anti-HCV positive patients, who were not tested for
HCV-RNA, and HCV-RNA positive patients, who did not receive treatment, were called for a follow-up visit in the outpatient clinic.
Results: The prevalences of anti-HCV positivity and viremia among patients were 2.24% and 0.67%, respectively. A HCV-RNA test was
ordered in 71.7% of the anti-HCV positive patients. Antiviral treatment was not given to 44.4% of the viremic patients. Of the patients,
who were called for a follow-up visit in the outpatient clinic, 3.9% attended the visit. Of these patients, 0.8% were HCV-RNA positive
and 0.7% received treatment.
Conclusion: Although the rate of HCV-RNA testing was relatively high in patients with anti-HCV positivity, almost half of them did not
receive treatment. We could reach only one-third of the patients, who were called for a follow-up visit, and only a few patients received
treatment. Individuals with anti-HCV positivity should be referred to a specialist without delay and HCV-RNA testing should be
performed immediately to achieve HCV elimination targets. The likelihood of difficulties in reaching patients later should be considered.
Key words: Hepatitis C virus, chronic hepatitis C, elimination, prevalence

1. Introduction
Hepatitis C virus (HCV) infection is one of the most
important causes of liver cirrhosis and hepatocellular
cancer all over the world. Therefore, HCV infection is
accepted as an important public health threat [1]. It is
estimated that 58 million individuals are infected with
HCV globally and this figure is estimated to be 434,000
(274,000–959,000) in Turkey. The mean prevalence of
viremic cases is 0.8% (0.5%–1.7%) in Turkey1.
HCV infection is often asymptomatic. Acute HCV
infection becomes chronic at a rate of 70%–85%. The risk
of liver cirrhosis within 20 years ranges from 15% to 30%
in patients with chronic hepatitis C (CHC).1 Because the
infection is often asymptomatic, the diagnosis may be
delayed and patients may present with the end-stage liver

disease years later. The diagnosis of CHC is often made
incidentally at blood donation, prepregnancy testing,
premarital or preoperative screening, or during routine
follow-ups of hemodialysis patients [2].
Because of the high replication rate and the lack of a
proofreading mechanism in the causative virus, effective
vaccines are not currently available against HCV infection.
Therefore, the control of the disease is based on the
treatment of infected patients and the prevention of new
transmissions. Fortunately, there have been revolutionary
developments in the treatment of CHC over the last 10
years. With the introduction of direct-acting antivirals
(DAAs), CHC has become curable at rates of >95%. The
World Health Organization (WHO) introduced a strategy
for HCV elimination in 2016, aiming to diagnose 90% of
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patients, treat 80% of patients, and achieve a 65% reduction
in HCV-related mortality by the year 2030 [3]2. In line with
this goal, the Turkey Viral Hepatitis Prevention and Control
Program was introduced in Turkey in 2018.3With this
study, we aimed to contribute to HCV elimination targets.
We aimed to find the rate of viremia among patients with
positive anti-HCV tests and the rate of antiviral treatment
administration to viremic patients. Moreover, we aimed to
reach two groups of patients including those, who tested
positive for anti-HCV antibodies but were not tested for
HCV-RNA, and those, who were positive for HCV-RNA
but received no treatment.
2. Materials and methods
This is a retrospective and single-center study, which was
conducted in Tokat Gaziosmanpaşa University University
Research and Application Hospital in the period between
January 2010 and January 2020. Data were accessed
through the hospital automation system. The study was
approved by the local ethics committee (Clinical Research
Ethics Committee of Tokat Gaziosmanpaşa University
University, School of Medicine, 20-KAEK 258).
Anti-HCV test results obtained in Tokat Gaziosmanpaşa
University University Research and Application Hospital
in the period between January 2010 and January 2020
were reviewed retrospectively and reactive results were
included in the study. Clinical departments were recorded,
from which the tests were ordered revealing anti-HCV
positivity. These departments were classified under the
following five categories as the departments of emergency,
internal medicine, surgery, infectious diseases, and
gastroenterology. The frequency of HCV-RNA testing
in anti-HCV positive patients, the prevalence of viremic
patients, rate of starting antiviral treatment in viremic
patients, treatment responses, and distribution of HCV
genotypes were investigated.
Patients with anti-HCV positivity but not tested for
HCV-RNA, patients with HCV-RNA positivity, who did
not receive treatment, and patients, who relapsed, were
recorded and contacted by phone. The phone numbers of
these patients were retrieved from the hospital automation
system. Unavailable patients were called at least twice. On
the phone call, patients were informed about test results,
and, if they were interested, it was explained that they could
apply to the infectious diseases department for further
examination and treatment. We ensured privacy when
interviewing a patient. The spouse or first-degree relatives
were not informed. If the patient died and a first-degree

relative answered the phone, no detailed information
was provided about the patient’s condition. However,
such individuals were informed that they could apply to
our outpatient clinic for testing for screening purposes to
detect a potential infection.
Telephone conversations were carried out following
the steps listed below:
1. Self-introduction of the caller.
2. The name and surname of the patient were confirmed.
3. The patient’s consent was obtained for the interview.
4. Patients were asked whether they were informed
about the results of anti-HCV testing performed in our
hospital.
5. It was explained to uninformed patients that they
could attend a follow-up visit in our outpatient clinic to
discuss results, undergo further examinations, and receive
treatment.
6. Patients, who had already been informed about antiHCV testing results, were asked whether additional tests
were performed and if they received any treatment.
7. Patients, who moved to another city, were advised to
apply to infectious diseases or gastroenterology specialists.
2.1. Statistical analysis
The Statistical Package for Social Sciences (SPSS) 22 (IBM
Corp., Armonk, NY, USA) software was used for data
analysis. The conformity of the variables to the normal
distribution was examined using visual (histograms
and probability graphs) and analytical methods
(Kolmogorov-Smirnov and Shapiro-Wilk tests). For
descriptive statistics, numbers and percentages were used
for categorical variables, mean ± standard deviation was
used for normally distributed continuous variables, and
median (minimum-maximum) was used for nonnormally
distributed continuous variables.
3. Results
Anti-HCV tests performed in Tokat Gaziosmanpaşa
University University Research and Application Hospital
in the period between January 2010 and January 2020 were
reviewed. When repeat tests for individual patients were
excluded, we found that anti-HCV tests were performed on
132,215 patients, and anti-HCV positivity was revealed in
3249 of these patients. Anti-HCV prevalence was 2.24%. Of
the patients, 62.6% (n = 2038) were women and the mean
age was 56.38 ± 18.3 years.
HCV-RNA testing was ordered for 2297 (70.7%) of
the anti-HCV positive patients. In the period after 2016,
when second-generation DAAs became available in our
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country, the rate of HCV-RNA testing was found to be
57.7% (424/734) in patients with anti-HCV positivity.
HCV-RNA positivity was detected in 899 (27.7%) of all
anti-HCV positive patients. The prevalence of viremic
patients was 0.67 (899/132,215). Of the viremic patients,
65.7% (n = 591) were women and the mean age was 61.44
± 12.66 years. Antiviral treatment was not started in 399
(44.4%) of the viremic patients. Of 500 patients treated,
466 (51.8%) were cured, and 34 (3.8%) relapsed (Figure 1).
The distribution of patients with anti-HCV positivity
but with no HCV-RNA testing by clinical departments was
shown in Table 1. It was found that 85.4% (n = 813) of the
patients without HCV-RNA testing had not been referred
to infectious diseases and/or gastroenterology clinics.
Because HCV genotyping was required for the selection
and determining the duration of antiviral therapy during
the period of the study, the rates of genotype testing were
also investigated. Genotyping was studied in 62.6% (n
= 563) of 899 viremic patients. The HCV genotypes of
patients are presented in Table 2.

The telephone numbers of 73.3% (n = 698) of the 952
patients not tested for HCV-RNA were available in the
hospital automation system. Although all patients were
called twice, 47.2% (n = 450) could not be reached. The
telephone numbers of 79.2% (n = 343) of the 433 HCVRNA positive patients (399 untreated, 34 relapsed) were
available in the system. In this group of patients, 35.5%
(n = 154) did not answer the call. The following reasons
were noted for unavailable patients, including patients’
not answering the phone, the phone being turned off, busy
signals, and incorrect and invalid phone numbers. Finally,
only 54 (3.9%) of the 1385 patients, who were planned to be
invited by a phone call for a follow-up visit at the hospital,
attended visits to be tested or treated. HCV-RNA positivity
was detected in 12 patients. Of these 12 patients, 10 were
treated with DAA. Of the remaining two patients, one
did not accept the treatment, and the other was a foreign
national and treatment costs were neither affordable for
this patient nor covered by the social security institution
(Figure 2).

Figure 1. Distribution of anti-HCV positive patients by HCV-RNA test results and antiviral treatment status.
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Table 1. Distribution of nontesting for HCV-RNA among anti-HCV positive patients by clinical departments.
Departments

Nontesting for HCV-RNA/anti-HCV positivity (n)

Rates of nontesting for HCV-RNA (%)

Emergency department

47/60

78.3

Surgical outpatient clinics

383/1343

28.5

Internal medicine outpatient clinics

383/1431

26.7

Gastroenterology

98/923

10.3

Infectious diseases

38/783

4.8

Total

952/4540×

×The figure is greater than the sum because testings were ordered by more than one clinic for individual patients.

Figure 2. Outcome in anti-HCV positive patients, who were not tested for HCV-RNA, and in
HCV-RNA positive patients, who did not receive treatment or relapsed.
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Table 2. Genotype distribution.
Genotype

n

%

1× (unspecified subtype)

73

13

1b

439

78.1

1a

26

4.6

3

13

2.3

2

5

0.9

4

5

0.9

1a+1b

1

0.2

1a+3

1

0.2

Total

563

100

×Genotype subtyping was not performed for patients before the year 2013.

4. Discussion
Due to the COVID-19 pandemic, people with chronic
diseases all over the world are at serious risk in terms of
the odds of not only being infected with SARS-CoV-2 but
experiencing poor disease management as well.4 Hepatitis
C infection is acquired through parenteral exposure
and CHC may develop while remaining asymptomatic
in the majority of patients. However, CHC can cause
cirrhosis and liver cancer if not diagnosed. Therefore,
it is necessary to diagnose, treat, and regularly follow
up on such patients. Because of such characteristics of
disease management, CHC is among the chronic diseases
most affected by the pandemic process [4]. As in other
chronic diseases, significant problems are anticipated in
the follow-up of CHC patients and a potential wave of
liver-related morbidity and mortality during and after the
pandemic is predicted. During the pandemic, significant
disruptions have occurred in patients’ access to treatment
and diagnostic approaches.5 In our study, we aimed to
achieve cure in a significant number of patients but only
3.9% of the patients presented to the outpatient clinic and
only 0.7% of the patients were treated.
After the introduction of HCV elimination targets in
our country, similar studies to our study were published
from many hospitals aiming to reach anti-HCV positive
patients. While some of these studies included only
patients, who were tested for anti-HCV antibodies
preoperatively, others included all patients tested for antiHCV for any purpose, as we did in our study. We reviewed
serum test results of 132,215 patients and this is the highest
number of patient serum samples tested, reviewed, and

included in a study. The prevalence of anti-HCV positivity
in the studies from Turkey ranges from 0.28% to 2.86%
and the prevalence of viremic patients varies between
0.05% and 0.38% [2,5-8]. In our study, the prevalences of
anti-HCV positivity (2.24%) and viremic patients (0.67%)
were higher compared to similar studies from Turkey.
Anti-HCV antibody testing is the first-line test for the
diagnosis of HCV infection. In the presence of a reactive
anti-HCV antibody test result, demonstration of viremia
is required to confirm active infection. For this purpose,
the presence of HCV-RNA should be demonstrated
by molecular methods. Despite persisting anti-HCV
positivity, HCV-RNA becomes negative in patients with
sustained virological response, resulting in spontaneous
resolution or cure [9]. In our study, we found that HCVRNA testing was performed in 71.7% of the patients
with anti-HCV positivity. This rate is higher than those
reported by similar studies [2,5-8]. The lack of HCV-RNA
testing in approximately one-third of patients may indicate
that clinicians did not follow up on test results after placing
test orders. In our study, we also evaluated the frequency
of HCV-RNA test orders for anti-HCV positive patients by
clinics. We found that a significant portion (78.3%) of the
patients admitted to the emergency department was not
tested for HCV-RNA. Because an emergency department
is an intense work environment, we think that patients
may not have been informed about test results and such
patients may not have been referred to relevant specialists.
In the internal medicine and surgical clinics, approximately
one-fourth of the patients were not tested for HCV-RNA.
We think that this may be due to the lack of information.

Centers for Disease Control and Prevention (2021). What to Know About Liver Disease and COVID-19 [online]. Website https://www.cdc.gov/
coronavirus/2019-ncov/need-extra-precautions/liver-disease.html [accessed 19 July 2021].
4
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The lowest rate of the lack of HCV-RNA testing was in
the infectious diseases department. We think that the
reason for the failure to schedule further examinations in
gastroenterology and/or infectious diseases clinics may
have been unattended follow-up visits by patients for the
discussion of test results.
Since CHC is a curable disease, antiviral treatment
is very important to prevent not only complications but
also disease transmission. The TURHEP study, which was
published in 2015, reported that approximately 514,000
patients were infected with HCV in Turkey; 5500 of these
patients were newly diagnosed, and only 4200 (0.8%)
patients received antiviral treatment [10]. The low rate
of access to antiviral treatment among patients infected
with HCV is not unique to our country. In a study from
the United Kingdom, it was reported that only 39% of
people infected with HCV were referred to hepatology
clinics, and 22% could receive treatment [11]. Studies
from different countries have shown that 50%–80% of the
patients infected with HCV were not diagnosed and less
than 20% received antiviral treatment [12]. In our study,
we found that 44.4% of viremic patients did not receive
treatment. Moreover, when viremic patients, who were not
tested for HCV-RNA, are included, this calculation will
result in a lower figure than previously found. Because of
the retrospective design of our study, we could not identify
reasons for not starting treatment for viremic patients.
We suggest that the reasons for failure to start treatment
may include patients’ comorbidities, biopsy findings
not meeting the treatment criteria relevant to the study
period, the patient’s refusal of interferon treatment, and
the patient’s failure to attend follow-up visits.
Genotype 1 is the most common worldwide, accounting
for 46.2% of all HCV cases. Of those, who underwent
subtyping, 31% are genotype 1a and 68% are genotype
1b. The second most common (30.1%) type is genotype 3.
Genotypes 2, 4, and 6 constitute 22.8% of all cases, while
the frequency of genotype 5 is less than 1% [13]. Genotype
1 is the most common subtype in studies from Turkey.
Genotype 3 is the second most common subtype followed
by genotypes 2 and 4. Subtype 1b constitutes the majority
of genotype 1 cases [10,14]. Our results are similar to those
reported in the literature.
The percentage of patients presenting to our hospital
to be tested or treated was considerably lower than we
expected. This result shows that patients should be informed
about the positive test results immediately. Otherwise, it is
difficult to reach such patients later. In 85.4% of the cases,
HCV-RNA was not tested and these patients did not present
to the infectious diseases or gastroenterology outpatient
clinics. This appears to result from inadequate information
delivery to patients by physicians of other specialties and
the failure to refer patients to relevant clinics. A solution to

this problem can be the creation of alert signals in hospital
automation systems. For patients with positive anti-HCV
test results, a specific alert sign may appear and remind
the physician of referring this patient to the infectious
diseases or gastroenterology outpatient clinic. Information
sharing meetings about HCV can be organized to include
physicians from all specialties and raise awareness.
In the study by Erbay et al., patients, who were
found to be positive for anti-HCV antibodies during the
preoperative screening procedure, were called by phone
and asked whether they received information about test
results. It was found that 29.8% of individuals, who were
informed of test results, had never visited an infectious
diseases/gastroenterology outpatient clinic. Moreover,
14.2% of individuals, who were newly diagnosed and
informed by the surgeon, did not see a specialist [2]. In
a study from the USA, anti-HCV and HCV-RNA positive
individuals, who were diagnosed in the period between
the years 2001 and 2008, were informed by a letter and
a follow-up questionnaire was administered to those
individuals 6 months later. It was reported that 50.3% of
the respondents knew that they were infected with HCV,
and 22.9% did not see a specialist [12]. In our study, we
believe that the number of patients, who attended the
follow-up visits after phone calls, was small not only
because of the lack of awareness of HCV infection but
also because of factors associated with the COVID-19
pandemic. One may suggest that patients would have liked
to avoid waiting in a crowded hospital hall and catching
the infection.
A major limitation of our study is its retrospective
design. Because of the retrospective design of the study, we
could not clarify why HCV-RNA positive individuals did
not receive treatment. Another limitation was that the phone
numbers of the patients were incomplete or incorrectly
recorded in the hospital automation system. Therefore, a
significant number of patients could not be reached.
5. Conclusion
It is difficult to access anti-HCV positive patients later.
For this reason, patients with a positive test result should
be informed timely and referred to infectious diseases or
gastroenterology specialists without delay. Information
can be provided at meetings with the participation of
experts of several relevant specialties. Alerts can be created
in the hospital automation system to notice physicians.
Alerts can be in the form of buttons with a warning letter
dedicated to directing anti-HCV positive patients to
infectious diseases or gastroenterology specialists.
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